108 related articles for article (PubMed ID: 27514014)
1. Analysis of residual content of used syringes collected from low threshold facilities in Lausanne, Switzerland.
Lefrançois E; Esseiva P; Gervasoni JP; Lucia S; Zobel F; Augsburger M
Forensic Sci Int; 2016 Sep; 266():534-540. PubMed ID: 27514014
[TBL] [Abstract][Full Text] [Related]
2. Drug residues in used syringes in Switzerland: A comparative study.
Lefrançois E; Augsburger M; Esseiva P
Drug Test Anal; 2018 May; 10(5):874-879. PubMed ID: 29111580
[TBL] [Abstract][Full Text] [Related]
3. Drug analysis of residual content of used syringes: a new approach for improving knowledge of injected drugs and drug user practices.
Néfau T; Charpentier E; Elyasmino N; Duplessy-Garson C; Levi Y; Karolak S
Int J Drug Policy; 2015 Apr; 26(4):412-9. PubMed ID: 25449054
[TBL] [Abstract][Full Text] [Related]
4. Substances injected at the Sydney supervised injecting facility: A chemical analysis of used injecting equipment and comparison with self-reported drug type.
Lefrancois E; Belackova V; Silins E; Latimer J; Jauncey M; Shimmon R; Mozaner Bordin D; Augsburger M; Esseiva P; Roux C; Morelato M
Drug Alcohol Depend; 2020 Apr; 209():107909. PubMed ID: 32145660
[TBL] [Abstract][Full Text] [Related]
5. Substances detected in used syringes of injecting drug users across 7 cities in Europe in 2017 and 2018: The European Syringe Collection and Analysis Project Enterprise (ESCAPE).
Brunt TM; Lefrançois E; Gunnar T; Arponen A; Seyler T; Goudriaan AE; McAuley A; McKeown DA; Detrez V; Csorba J; Deimel D; Auwärter V; Kempf J; Karolak S; Nefau T
Int J Drug Policy; 2021 Sep; 95():103130. PubMed ID: 33487529
[TBL] [Abstract][Full Text] [Related]
6. Analytical findings in used syringes from a syringe exchange program.
Fiorentin TR; Logan BK
Int J Drug Policy; 2020 Jul; 81():102770. PubMed ID: 32442881
[TBL] [Abstract][Full Text] [Related]
7. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.
Emmanuelli J; Desenclos JC
Addiction; 2005 Nov; 100(11):1690-700. PubMed ID: 16277629
[TBL] [Abstract][Full Text] [Related]
8. Pattern of injecting drug uses and HIV-1 infection: analysis from needle exchange program.
Tellado I; Moran N; Vargas Vidot J; Yamamura Y
Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):1091-6. PubMed ID: 9449543
[TBL] [Abstract][Full Text] [Related]
9. A high proportion of users of low-threshold facilities with needle exchange programmes in Switzerland are currently on methadone treatment: implications for new approaches in harm reduction and care.
Gervasoni JP; Balthasar H; Huissoud T; Jeannin A; Dubois-Arber F
Int J Drug Policy; 2012 Jan; 23(1):33-6. PubMed ID: 21705205
[TBL] [Abstract][Full Text] [Related]
10. More free syringes, fewer drug injectors in the case of Spain.
Bravo MJ; Royuela L; Barrio G; de la Fuente L; Suarez M; Teresa Brugal M
Soc Sci Med; 2007 Oct; 65(8):1773-8. PubMed ID: 17658207
[TBL] [Abstract][Full Text] [Related]
11. Multiple access to sterile syringes for injection drug users: vending machines, needle exchange programs and legal pharmacy sales in Marseille, France.
Moatti JP; Vlahov D; Feroni I; Perrin V; Obadia Y
Eur Addict Res; 2001 Mar; 7(1):40-5. PubMed ID: 11316925
[TBL] [Abstract][Full Text] [Related]
12. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.
Broz D; Wejnert C; Pham HT; DiNenno E; Heffelfinger JD; Cribbin M; Krishna N; Teshale EH; Paz-Bailey G;
MMWR Surveill Summ; 2014 Jul; 63(6):1-51. PubMed ID: 24990587
[TBL] [Abstract][Full Text] [Related]
13. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention.
Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L
Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367
[TBL] [Abstract][Full Text] [Related]
14. A snapshot of injecting drug consumption from the analysis of used syringes within the Medically Supervised Injecting Centre in Sydney, Australia.
Fursman H; Finch E; Xiao L; Lefrançois E; Gupta A; Bartlett M; Latimer J; Chadwick S; Roux C; Morelato M
Drug Alcohol Rev; 2024 Mar; 43(3):787-798. PubMed ID: 38145366
[TBL] [Abstract][Full Text] [Related]
15. Estimating national-level syringe availability to injecting drug users and injection coverage: Switzerland, 1996-2006.
Arnaud S; Jeannin A; Dubois-Arber F
Int J Drug Policy; 2011 May; 22(3):226-32. PubMed ID: 21600753
[TBL] [Abstract][Full Text] [Related]
16. [The initial experience in supervised injecting facilities in Denmark].
Axelsson A; Hvam F; Bonde M; Olsen ML; Kiørboe E; Hoff-Lund O; Abildgaard M; Iversen K
Ugeskr Laeger; 2012 Sep; 174(39):2286-9. PubMed ID: 23006221
[TBL] [Abstract][Full Text] [Related]
17. Which illicit drugs are injected in Oslo? A study based on analysis of drug residues in used injection equipment and self-reported information.
Gjerde H; Bretteville-Jensen AL; Bache-Andreassen L; Hanoa K; Furuhaugen H; Brochmann GW; Vindenes V
Scand J Public Health; 2023 Feb; 51(1):21-27. PubMed ID: 34538164
[TBL] [Abstract][Full Text] [Related]
18. An external evaluation of a peer-run "unsanctioned" syringe exchange program.
Wood E; Kerr T; Spittal PM; Small W; Tyndall MW; O'Shaughnessy MV; Schechter MT
J Urban Health; 2003 Sep; 80(3):455-64. PubMed ID: 12930883
[TBL] [Abstract][Full Text] [Related]
19. Access to harm reduction and HIV-related treatment services inside Indian prisons: experiences of formerly incarcerated injecting drug users.
Chakrapani V; Kamei R; Kipgen H; Kh JK
Int J Prison Health; 2013; 9(2):82-91. PubMed ID: 25758440
[TBL] [Abstract][Full Text] [Related]
20. Malaysia and harm reduction: the challenges and responses.
Reid G; Kamarulzaman A; Sran SK
Int J Drug Policy; 2007 Mar; 18(2):136-40. PubMed ID: 17689356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
